

Interaction Report**Report ID:****Date Produced:**

03 May 2025

Hepatology Treatment**Co-medications**

Bulevirtide

Irbesartan

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown. Please note that some co-medications with a green classification may require dose adjustment due to hepatic impairment.

For full details of all interactions, see www.hepatology-druginteractions.org.

Description of the interactions**Drugs that should not be coadministered (RED)****Bulevirtide + Irbesartan**

Coadministration has not been studied. Bulevirtide is catabolized by peptidases and elimination occurs through binding to NTCP. Bulevirtide is catabolized by peptidases and elimination occurs through binding to NTCP. Coadministration with NTCP inhibitors (e.g. irbesartan) is not recommended as it can alter bulevirtide elimination.